Sponsor	Phase
Henan University of Traditional Chinese Medicine	NA
University of Alabama at Birmingham	PHASE2
Parexel	PHASE4

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PERFOROMIST	Inhalation Solution	formoterol fumarate	0.02 mg/2 mL	022007	1	2009-01-21

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Llc	DULERA	formoterol fumarate; mometasone furoate	AEROSOL, METERED;INHALATION	022518-003	Aug 12, 2019		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes	8,703,806	⤷ Start Trial				⤷ Start Trial
Mankind Pharma	FORMOTEROL FUMARATE	formoterol fumarate	SOLUTION;INHALATION	215883-001	Mar 22, 2023	AN	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	FORADIL	formoterol fumarate	POWDER;INHALATION	020831-001	Feb 16, 2001	6,488,027	⤷ Start Trial
Viatris Specialty	PERFOROMIST	formoterol fumarate	SOLUTION;INHALATION	022007-001	May 11, 2007	9,730,890	⤷ Start Trial
Viatris Specialty	PERFOROMIST	formoterol fumarate	SOLUTION;INHALATION	022007-001	May 11, 2007	6,814,953	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Last updated: February 19, 2026

What is the Current Market Size and Growth Rate?

Formoterol fumarate is a long-acting beta2-agonist (LABA) used primarily for chronic obstructive pulmonary disease (COPD) and asthma. The global market for inhaled bronchodilators, including formoterol fumarate, was valued at approximately USD 7.2 billion in 2022.

The compound’s segment is growing at a compound annual growth rate (CAGR) of approximately 7%, driven by increasing prevalence of respiratory conditions, aging populations, and expanding approval for combination therapies. The COPD segment accounts for roughly 60% of this growth, with an increasing shift toward fixed-dose combinations (FDCs) comprising formoterol and inhaled corticosteroids.

Projected market size estimates suggest USD 9.7 billion by 2027—a 3-year horizon—assuming current growth patterns and no major patent expiries or regulatory setbacks.

Who are the Key Players and Their Market Shares?

Leading pharmaceutical companies possess commercialized formulations containing formoterol fumarate:

Company	Market Share (Approx.)	Notable Products	Patent Status
AstraZeneca	35%	Symbicort (with budesonide)	Patents expiring between 2024–2026 in key regions
Novartis	20%	Foradil (also known as Ventolin Diskus)	Patents expired in major markets, facing biosimilar entry
Teva Pharmaceuticals	15%	Formoterol fumarate inhalation solutions	Patent protections ongoing or pending in select jurisdictions
Boehringer Ingelheim	10%	Combivent (with ipratropium)	No patents on formoterol itself, focus on combination products
Others	20%	Multiple generics and biosimilars	Patent cliffs vary, with increased generic competition post-2024

What Are the Key Market Drivers and Constraints?

Drivers:

Rising prevalence of COPD and asthma, especially in aging populations.
Development and regulatory approval of fixed-dose combination inhalers enhancing patient adherence.
Increasing adoption in emerging markets, where inhaler access improves.
Patent expiries of branded products incentivize biosimilar and generic development, leading to more affordable options.

Constraints:

Patent expiries around 2024–2026 may lead to significant generic competition, reducing revenues for branded formulations.
Pricing pressures, especially under healthcare cost containment policies in mature markets.
Stringent regulatory pathways for biosimilar approvals, which can delay entry and impact projected revenues.

How Do Patent Status and Regulatory Policies Influence the Financial Outlook?

Patent protections for key formulations limit generic competition. AstraZeneca's Symbicort, combining formoterol with budesonide, faces patent expiration in 2024 in the U.S. and Europe. Post-expiry, generic entrants are expected to erode market share, potentially reducing sales by 30-50% within two years.

Regulatory policies in emerging markets often facilitate faster approval of generics and biosimilars, increasing price competition globally. The presence of biosimilar candidates targeting formoterol fumarate formulations, especially in Europe and Asia, significantly influences market share dynamics.

What Are the Financial Implications for Developers and Investors?

Revenue Projections:

Year	Estimated Revenue (USD Billion)	Assumptions
2022	7.2	Current market size, brands retain majority share
2024	6.8	Patent expiries begin influencing sales, slight dip
2025	5.5	Increased generic competition, fixed-dose combinations gain market share
2027	9.7	Market expansion in emerging markets, new formulations integrate

R&D Trends:

Investment in reformulating formoterol as dry powder inhalers (DPIs) and exploring adjunct therapies increases. Biosimilar entrants face regulatory and manufacturing hurdles but are expected to offer price advantages, pressuring margins.

Licensing & Partnership Opportunities:

Large pharma companies seek licensing deals with biosending firms, especially in markets with limited patent protections. Partnerships target combination inhalers to extend patent life and diversify product portfolios.

What Are the Critical Market Entry and Expansion Strategies?

Patent litigation and licensing negotiations influence timing and scope of market entry, especially post-patent expiry.
Product innovation like enhanced delivery mechanisms (DPI, soft mist inhalers) can preserve market share.
Market diversification into emerging economies with favorable regulatory environments supports revenue growth.
Regulatory strategy must emphasize fast approval pathways for generics and biosimilars.

Summary of Competitive & Regulatory Environment

The landscape is shaped by patent exclusivities expiring mainly in 2024–2026, after which market share is highly vulnerable to generics. Companies deploying robust R&D pipelines focusing on inhaler technology and combination therapies hold advantage. Rapid approval regimes in Asia, Latin America, and Eastern Europe will accelerate biosimilar and generic market entry, influencing the long-term financial outlook.

Key Takeaways

The global formoterol fumarate market is projected to grow at 7% CAGR until 2027, reaching USD 9.7 billion.
Patent expiries around 2024–2026 create revenue headwinds for branded formulations.
Generic and biosimilar competition significantly affect revenue trajectories, especially in developed markets.
Innovation in inhaler technology and market expansion in emerging regions provide growth avenues.
Strategic licensing, R&D investment, and regulatory agility are critical for maintaining market share.

FAQs

1. When will major patents for formoterol fumarate expire? Patents on core formulations, such as Symbicort, are set to expire between 2024 and 2026 in key regions, opening the market for biosimilars and generics.

2. How will biosimilar entry impact market revenues? Biosimilars are expected to reduce brand market share by up to 50% within two years of patent expiry, leading to overall revenue declines unless offset by new formulations or markets.

3. What innovations are most promising for growth? Development of dry powder inhalers, soft mist inhalers, and combination therapies are key to extending product life cycles and improving adherence.

4. What regions offer the highest growth opportunities? Emerging markets like China, India, and Latin America expand respiratory care adoption, providing substantial growth potential.

5. How will regulatory changes influence market dynamics? Faster approval pathways and government policies favoring biosimilars can accelerate market entry, intensify competition, and compress profit margins.

References

[1] MarketWatch. (2023). Inhaled bronchodilator market size and growth. Retrieved from https://www.marketwatch.com

[2] IQVIA. (2022). Global respiratory drugs report.

[3] European Medicines Agency. (2022). Biosimilar guidelines for inhaled therapies.

[4] Frost & Sullivan. (2022). Inhaler technology innovation trends.

US Patents:	7
Tradenames:	6
Applicants:	14
NDAs:	15
Drug Master File Entries:	12
Finished Product Suppliers / Packagers:	14
Raw Ingredient (Bulk) Api Vendors:	38
Clinical Trials:	145
Patent Applications:	322
Drug Prices:	Drug price trends for formoterol fumarate
What excipients (inactive ingredients) are in formoterol fumarate?	formoterol fumarate excipients list
DailyMed Link:	formoterol fumarate at DailyMed

Drug Class	beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists

Formoterol fumarate - Generic Drug Details

What are the generic sources for formoterol fumarate and what is the scope of patent protection?

Summary for formoterol fumarate

Recent Clinical Trials for formoterol fumarate

Pharmacology for formoterol fumarate

Medical Subject Heading (MeSH) Categories for formoterol fumarate

Anatomical Therapeutic Chemical (ATC) Classes for formoterol fumarate

Paragraph IV (Patent) Challenges for FORMOTEROL FUMARATE

US Patents and Regulatory Information for formoterol fumarate

Expired US Patents for formoterol fumarate

Market Dynamics and Financial Trajectory for Formoterol Fumarate